Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 127

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 127
---
  |
| Oct. 6, 2014  |     | IL 235270     |     | Apparatus for treatment of cavities in a human body                                                            |     | Israel                                        |     | Delivery device                    |     | Utility patent  |     | Oct. 6, 2034  |
| Dec. 14, 2016 |     | CN 108472413  |     | Organic solvent free compositions comprising protein-polymer conjugates and uses thereof                       |     | China                                         |     | Ready for use acetone-free product |     | Utility patent  |     | Dec. 14, 2036 |
| Dec. 14, 2016 |     | IN 457479     |     | Organic solvent free compositions comprising protein-polymer conjugates and uses thereof                       |     | India                                         |     | Ready for use acetone-free product |     | Utility patent  |     | Dec. 14, 2036 |
| Dec. 14, 2016 |     | IL 259891     |     | Organic solvent free compositions comprising protein-polymer conjugates and uses thereof                       |     | Israel                                        |     | Ready for use acetone-free product |     | Utility patent  |     | Dec. 14, 2036 |

<div align='center'>Patent applications (pending):

78</div>

| 1 | Nominal expiration date based on earliest effective filing date. Not including any possible future patent term extensions or adjustments. |

Data Agreement with TiGenix

We entered into a data agreement with TiGenix dated July 20, 2015, or the TiGenix Data Agreement, pursuant to which we licensed microfracture historical data that TiGenix compiled in a study that TiGenix conducted in 2011. The FDA has allowed us to use the licensed data as control data for our pivotal clinical trial for PMA.

The TiGenix Data Agreement grants the Company the right to use the control data on a non-royalty-bearing, paid-up, worldwide and non-exclusive basis for any purpose, including for use in connection with regulatory filings for the Company’s products, for a term for 30 years unless earlier terminated by the Company upon 30 days’ written notice, with or without cause. TiGenix is only permitted to early terminate the TiGenix Data Agreement if the Company fails to cure a material breach of the TiGenix Data Agreement within 60 days after receiving written